Vorapaxar is a synthetic antiplatelet active pharmaceutical ingredient (API) that selectively inhibits Protease-Activated Receptor-1 (PAR-1). It is primarily available as Vorapaxar Sulfate, the pharmaceutical salt form of the active compound. Vorapaxar belongs to the antiplatelet and antithrombotic class and works by blocking thrombin-mediated platelet activation through the PAR-1 receptor.
Vorapaxar has a complex chemical structure derived from the himbacine framework and contains multiple stereogenic centres. Because of its structural complexity, stereochemical purity, chemical purity and solid-state characteristics are important quality attributes during pharmaceutical API manufacturing and development.
Vorapaxar Sulfate is a white to off-white crystalline pharmaceutical substance with pH-dependent aqueous solubility. The compound is freely soluble in methanol and has limited solubility in several other organic and aqueous media. Its physicochemical properties are important considerations during pharmaceutical formulation, processing and API development.
The molecular formula of Vorapaxar Sulfate is C₂₉H₃₃FN₂O₄ · H₂SO₄, with a molecular weight of approximately 590.7 g/mol. The active moiety is Vorapaxar, while the sulfate component forms the pharmaceutical salt.
Vorapaxar acts through selective inhibition of the Protease-Activated Receptor-1 found on human platelets. Thrombin activates platelets through PAR-1, initiating a signalling pathway that contributes to platelet activation and aggregation. By selectively blocking PAR-1, Vorapaxar reduces thrombin-induced platelet activation.
This distinctive mechanism places Vorapaxar among specialized antiplatelet compounds used in pharmaceutical research and development. Its activity is different from antiplatelet agents that primarily target pathways involving ADP receptors or cyclooxygenase.
Vorapaxar Sulfate is characterized as a crystalline active pharmaceutical substance. It has seven chiral centres, making stereochemical control particularly important during synthesis and quality assessment. Regulatory characterization has established a stable anhydrous crystalline form of the active substance.
The compound demonstrates pH-dependent solubility and is more soluble under acidic conditions. Vorapaxar Sulfate is freely soluble in methanol, while its solubility in aqueous media decreases as the pH increases. These characteristics are relevant to pharmaceutical formulation and manufacturing processes.
The manufacture of Vorapaxar API involves a controlled multi-step chemical synthesis. Because the molecule contains multiple stereogenic centres and a structurally complex framework, manufacturing processes require careful control of reaction conditions and intermediate quality.
During API production, process controls are applied to maintain chemical purity and stereochemical integrity. Purification steps are used to remove process-related impurities and obtain Vorapaxar Sulfate with the required quality characteristics. The final active substance undergoes analytical evaluation to confirm identity, purity and consistency.
Quality control of Vorapaxar Sulfate involves the evaluation of several critical pharmaceutical attributes. Identity can be established using techniques such as infrared spectroscopy, mass spectrometry and nuclear magnetic resonance spectroscopy. HPLC methods are used for assay and related-substance evaluation.
Stereochemical purity is particularly important for Vorapaxar because of its multiple chiral centres. Manufacturing and analytical controls also address potential stereochemical impurities and the relevant cis-isomer. Residual solvents, water content, elemental impurities, particle size and crystalline form can also be evaluated as part of the API quality-control program.
Vorapaxar Sulfate can be characterized using advanced analytical techniques including IR spectroscopy, HPLC, mass spectrometry, ¹H-NMR and ¹³C-NMR. These methods provide information about molecular identity, chemical structure and chromatographic purity.
Solid-state characterization can be performed to evaluate the crystalline form of the API. Additional analytical procedures may be used for residual solvents, water content, elemental impurities and particle-size distribution. Together, these analytical approaches help establish the quality and consistency of Vorapaxar API.
Vorapaxar API is associated with pharmaceutical development involving antiplatelet and antithrombotic therapies. Its selective PAR-1 antagonistic activity makes it relevant to research involving thrombin-mediated platelet activation and aggregation.
The API may be used in pharmaceutical research, formulation development and manufacturing applications where Vorapaxar Sulfate is required as an active pharmaceutical ingredient. Its specialized mechanism of action makes appropriate quality characterization important throughout pharmaceutical development.
For pharmaceutical applications, Vorapaxar Sulfate should be evaluated for identity, assay, related substances, stereochemical purity, residual solvents, water content and solid-state characteristics. Appropriate analytical methods should be validated for their intended purpose, and the final release requirements should correspond to the applicable approved or validated API specification.
Because public regulatory documents do not disclose every numerical acceptance criterion for Vorapaxar Sulfate, unsupported numerical limits should not be presented as universal pharmaceutical specifications. The applicable manufacturer or regulatory specification should be used for final batch release.
Swapnroop Drugs & Pharmaceuticals provides pharmaceutical API solutions for pharmaceutical development and manufacturing requirements. Vorapaxar API and Vorapaxar Sulfate are relevant to pharmaceutical applications involving specialized antiplatelet compounds and PAR-1 antagonist research.
Consistent manufacturing processes, analytical characterization and quality control are important for maintaining the required quality of Vorapaxar API. Pharmaceutical manufacturers and development organizations can evaluate Vorapaxar Sulfate according to their technical, regulatory and commercial requirements.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |